Veeva has announced the expansion of its business consulting services to help life sciences organizations achieve “greater speed and efficiency” across the product development lifecycle.
The new €350m ($386m) biotechnology research center will help power Boehringer Ingelheim’s development of biopharmaceuticals, which account for around 50% of the company’s research pipeline.
BioNTech and the UK government have signed a wide-reaching Memorandum of Understanding (MoU): with one of the goals to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030.
Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
Biopharma industry in the US is rooted in a strong R&D sector, with the employment percentage being three times larger than the industry average, suggests PhRMA.
